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Abstract
Background: This study evaluated the effectiveness and safety of preoperative chemoradiotherapy with
capecitabine in patients with locally advanced resectable rectal cancer. This report summarizes the results of the
phase II study together with long-term (5-year) follow-up.
Methods: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of
the rectum entered the study. Radiation dose was 45 Gy delivered as 25 fractions of 1.8 Gy. Concurrent
chemotherapy with oral capecitabine 825 mg/m
2 twice daily was administered during radiotherapy and at
weekends. Surgery was scheduled 6 weeks after the completion of the chemoradiotherapy. Patients received four
cycles of postoperative chemotherapy comprising either capecitabine 1250 mg/m
2 bid days 1-14 every 3 weeks or
bolus i.v. 5-fluorouracil 425 mg/m
2/day and leucovorin 20 mg/m
2/day days 1-5 every 4 weeks (choice was at the
oncologist’s discretion). Study endpoints included complete pathological remission, proportion of R0 resections and
sphincter-sparing procedures, toxicity, survival parameters and long-term (5-year) rectal and urogenital morbidity
assessment.
Results: One patient died after receiving 27 Gy because of a pulmonary embolism. Fifty-six patients completed
radiochemotherapy and had surgery. Median follow-up time was 62 months. No patients were lost to follow-up. R0
resection was achieved in 55 patients. A complete pathological response was observed in 5 patients (9.1%); T-, N-
and overall downstaging rates were 40%, 52.9% and 49.1%, respectively. The 5-year overall survival rate, recurrence-
free survival, and local control was 61.4% (95% CI: 48.9-73.9%), 52.4% (95% CI: 39.3-65.5%), and 87.4% (95% CI: 75.0-
99.8%), respectively. In 5 patients local relapse has occurred; dissemination was observed in 19 patients and
secondary malignancies have occurred in 2 patients. The most frequent side-effect of the preoperative combined
therapy was dermatitis (grade 3 in 19 patients). The proportion of patients with severe late (SOMA grade 3 and 4)
rectal, bladder and sexual toxicity was 40%, 19.2% and 51.7%, respectively.
Conclusions: This study confirms data from other non-randomised studies that capecitabine-based preoperative
chemoradiation is a feasible treatment option for locally advanced rectal cancer, with positive 5-year overall
survival, recurrence-free survival, and local control rates.
Introduction
Surgical resection remains the cornerstone of treatment
for patients with stage II or III rectal cancer. However,
curative resection is not always possible, and local
relapses or metastases occur even after high-quality sur-
gery. The use of a multidisciplinary approach, which
integrates surgery, radiotherapy and chemotherapy, has
become of increasing importance in this type of cancer.
For a number of years now preoperative (neoadju-
vant), rather than postoperative, radiotherapy has been
shown to be effective at reducing local relapses in a vari-
ety of cancer types [1-6]. In locally advanced rectal can-
cer, the addition of 5-fluorouracil (5-FU) to preoperative
radiotherapy has been shown to improve pathological
complete response rate, tumour downstaging [7] and
locoregional control [8,9] compared with radiotherapy
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improves locoregional control with less toxicity when
compared with postoperative radiochemotherapy [10].
Thus, preoperative radiochemotherapy with continuous
infusional 5-FU has become the standard of care in rec-
tal cancer, especially in tumours of the lower and mid-
dle rectum.
The oral fluoropyrimidine capecitabine has demon-
strated efficacy comparable with intravenous 5-FU in
metastatic colorectal cancer as well as in the adjuvant
setting in colon cancers [11-15]. Capecitabine has also
been investigated in a variety of protocols in rectal and
other gastrointestinal cancers in combination with
radiotherapy [16], with equivalence of capecitabine plus
radiotherapy and 5-FU plus radiotherapy as preoperative
therapy in locally advanced rectal cancer being demon-
strated in the systematic review by Saif et al. [17].
A recent retrospective analysis from a single centre
compared preoperative capecitabine to infusional 5-FU,
combined with radiotherapy: once again, capecitabine
showed more favourable results and higher downstaging
rates [18].
The aim of this study was to evaluate the effectiveness
and safety of preoperative chemoradiotherapy with cape-
citabine in patients with locally advanced rectal cancer.
Here we summarize the results of the phase II study
together and provide long-term (5-year) follow-up data.
Patients and Methods
Design and inclusion criteria
The trial design, eligibility criteria, treatment and initial
outcome variables have been published previously in
detail [19]. In brief, the trial included patients with his-
tologically confirmed locally advanced non-metastatic
resectable rectal cancer. Inclusion criteria were clinical
stage II or III [UICC TNM classification]; no prior
radiotherapy and/or chemotherapy; World Health Orga-
nization (WHO) performance status <2; age at diagnosis
of ≥18 years; and adequate bone marrow, liver, renal
and cardiac function (no history of ischemic heart dis-
ease). A history of prior malignancy other than non-
melanoma skin cancer or in situ carcinoma of the cervix
rendered the patient ineligible.
Prior to treatment, all patients received detailed oral
and written information on the treatment protocol and
possible side effects, and signed an informed consent.
The trial was approved by the ethic committees of
the Institute of Oncology, Ljubljana, Slovenia and of
the Republic of Slovenia and was in agreement with the
Declaration of Helsinki.
Treatment protocol
Radiotherapy was delivered using 15 MV photon beams
and four-field box technique, once per day, 5 days a
week for 5 weeks. The small pelvis received 45 Gy in 25
fractions over 5 weeks. Three-dimensional CT-based
treatment planning was performed. Patients were treated
in the prone position with a full bladder during irradia-
tion, and no devices were used to displace the small
bowel out of the irradiated volume. A multileaf collima-
t o rw a su s e df o rs h a p i n gt h ef i e l d sa n df o rt h ep r o t e c -
tion of normal tissues.
Chemotherapy with capecitabine was administered
concomitantly with radiotherapy at a dose of 825 mg/
m
2 twice daily (bid) during the whole period of radio-
therapy (days 1-33) without weekend breaks. Capecita-
bine doses were given 12 hours apart with one of the
doses being taken 2 hours prior to irradiation. If radio-
therapy was interrupted chemotherapy was not
administered.
Definitive surgery was scheduled 6 weeks after the
completion of the chemoradiotherapy. Surgical manage-
ment included a sphincter preservation approach when-
ever possible, using the total mesorectal excision
technique.
Four courses of chemotherapy were planned post-
operatively. This comprised either capecitabine 1250
mg/m
2 bid on days 1 to 14 every 3 weeks for 4 cycles or
bolus i.v. 5-fluorouracil 425 mg/m
2/day and leucovorin
20 mg/m
2/day on days 1 to 5 of each cycle repeated
every 4 weeks. The choice of post-operative chemother-
apy was left to the oncologist’s discretion.
During preoperative treatment, patients were evalu-
ated weekly for acute toxicity and compliance with the
protocol. Clinical examination and complete blood
count were performed and body weight was measured.
Toxic side effects were assessed according to National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
(version 2.0) [20]. Patients were followed every three
month for the first two years after the last cycle of adju-
vant chemotherapy and thereafter every six month up to
5th year.
The primary endpoint of the study was pathological
complete response (pCR) rate. Secondary endpoints
included the proportion of R0 resections, sphincter-spar-
ing procedures, toxicity evaluation, survival parameters
and long-term rectal and urogenital morbidity assess-
ment. To assess long-term rectal and urogenital morbid-
ity, all patients still alive, without recurrence of the
disease and with a minimum follow up of 1 year were
asked to complete a questionnaire about their rectal,
voiding and sexual function, which was assessed using
the Subjective, Objective, Management and Analytic/Late
Effects on Normal Tissues scale (SOMA/LENT) [21].
Statistics
The study aimed to evaluate whether a 12% pCR rate
could be produced using this treatment approach.
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an alpha error of 5% and a power of 80%, at least 55
evaluable patients were needed.
Overall survival was defined as the time from inclu-
sion to the date of death from any cause or to the date
of last follow-up. Relapse-free survival was defined as
t h et i m ef r o mi n c l u s i o nt ot h e first occurrence of dis-
ease relapse (local or distant), death or date of last fol-
low-up.
The Kaplan-Meier method was used to estimate the
rates of overall survival, relapse-free survival and local
relapse-free survival. A subgroup analysis was per-
formed regarding relapse-free survival and the para-
meters that were investigated included sex, age,
tumour location in the rectum (low, middle, upper
third), type of surgical procedure (abdominoperineal
amputation, sphincter sparing), and pathological T and
N status. The log-rank test was used to test the signifi-
cance between the subgroups for this endpoint. The
cumulative incidence approach was used to estimate
the rates for disease specific mortality, local recurrence
and distant metastasis.
Statistical analysis was performed using the SPSS sta-
tistical software package, version 12 (SPSS Inc., Chicago,
IL, USA).
Results
Patients’ baseline characteristics
Between June 2004 and January 2005, 57 patients
entered the study. The study population has been
described elsewhere [19]. Briefly, median age was 67
years, 75.5% were males, and 63.2% presented with stage
III disease. The WHO performance status was 1 in
12.3% of patients. The median distance of the tumour
from the anal verge was 5.5 cm (range 1-12 cm), and in
49.1% of patients the primary tumour was sited ≤5c m
from the anal verge. The flow of the patients through
the trial is shown in Figure 1.
Neoadjuvant therapy
One patient died after receiving 27 Gy of radiotherapy
as a result of a pulmonary embolism. The remaining 56
patients (98%) completed thep r e o p e r a t i v ec h e m o r a -
diotherapy according to the treatment protocol. The
Figure 1 Distribution of patients through the trial.
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Preoperative chemoradiotherapy grade 3 toxicity com-
prised radiodermatitis (19/56 patients; 33.9%), diarrhea
(2/56 patients; 3.6%), proctitis (1/56 patients; 1.8%),
infection (1/56 patients; 1.8%), impaired heart function
(1/56 patients; 1.8%), and leucopenia (1/56 patients;
1.8%).
Surgery
Surgery was performed following chemoradiotherapy
after a median of 45 days. In one patient only explora-
tive laparotomy was performed as the tumour was
deemed to be inoperable. As determined by histopatho-
logical examination of surgical specimens, the resection
was radical (R0) in 54 patients. In one patient, micro-
scopic foci of cancer cells were found in the radial surgi-
cal margin (R1 resection). The overall sphincter
preservation rate was 65.5% and in the 27 patients
where the tumour was located ≤5c mo ft h ea n a lv e r g e
the rate was 37%.
Post surgery, one patient died because of sepsis during
the early perioperative period. The most frequent perio-
perative complication was delayed wound healing (12/56
patients; 21.8%). Re-hospitalisation was necessary for 7
patients; 2 underwent another operation because of ana-
stomotic leak and ileus, respectively. Late surgical mor-
bidity included urosepsis (n = 1; 1.8%), pararectal
abscess (n = 1; 1.8%), and in 3 patients reoperation was
required (intra-abdominal abscess, enterocutane fistula
and stoma occlusion).
Thirty-six of the 39 patients (92.3%) returned the
SOMA/LENT questionnaire. The proportion of patients
with severe late (SOMA grade 3 and 4) rectal, bladder
and sexual toxicity was 40%, 19.2% and 51.7%, respec-
tively. More details on late toxicity have been reported
previously [22].
Tumour response
Tumour response was evaluated in 55 patients who had
definitive surgery. A complete pathological response was
observed in 5 patients (9.1%); T-, N- and overall down-
staging rates were 40%, 52.9% and 49.1%, respectively.
Adjuvant chemotherapy
Eleven patients never received adjuvant chemotherapy
either because of: death during the perioperative period
Figure 2 Local recurrence-free survival (n = 56).
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perative treatment in 1 patient (1.8%); postoperative
pathological echocardiogram in 1 patient (1.8%); surgical
complications in 5 patients (9%); and time from opera-
tion more than 8 weeks in 3 patients (5.5%). Postopera-
tive chemotherapy was administered to 44 of 55
radically operated patients (80%); 18/44 (40.9%) patients
received bolus 5-fluorouracil/leucovorin (5-fluorouracil
425 mg/m
2 plus leucovorin 20 mg/m
2 for 5 days, every
28 days) - 17 patients received 4 cycles and 1 patient
received 3 cycles because of a grade 3urinary infection;
26/44 patients (59.1%) received capecitabine 1250 mg/
m² for 14 days, every 21 days - 16 patients received 4
cycles, 1 patient received 1 cycle because of grade 3car-
diotoxicity and 1 patient received 3 cycles because of
prolonged grade 2 leukopenia. Eleven (20%) radically
operated patients did not received postoperative che-
motherapy. The choice of chemotherapy regimen was at
the discretion of the investigator.
Treatment outcome
The median follow-up time for patients still alive in this
trial was 62 months. The median time to disease
recurrence was 19.5 months (range: 3.3-58 months).
The pattern of first recurrence was predominantly dis-
tant metastases, which were observed in 18 patients
(33.3%). Local progression was the site of failure in 4
patients (7.4%), whereas 1 patient (1.8%) had synchro-
nous local and distant disease. The 5-year local control
rate was 87.4% (95% CI: 75.0-99.8) (Figure 2). In 5
patients local relapse occurred; dissemination was
observed in 19 patients and secondary malignancies
occurred in 2 patients. Nineteen patients (35.2%) devel-
oped distant metastases of which two were discovered
during surgery. The latest local and distant failures were
observed after 42 and 58 months, respectively. Relapse-
free survival rate was 52.4% (95% CI: 39.3-65.5) (Figure
3). It was found that survival was independent of gender
(p = 0.47), age (p = 0.58), tumour location in the rectum
(p = 0.32), type of operation (p = 0.22) and pathological
T status (p = 0.35), but it was significantly better in
patients with pathological negative nodes than in
patients with positive nodes (66.5% vs. 36.4%; p = 0.01).
As of April 2010, 22 patients (38.6%) of the entire study
population have died. One patient (1.8%) died of treat-
ment complications, 15 (26.3%) died of rectal cancer, 1
Figure 3 Recurrence-free survival (n = 57).
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patients of other causes (8.7%). The 5-year overall survi-
val rate was 61.4% (95% CI: 48.9-73.9) (Figure 4).
Discussion
Patients with locally advanced stage II/III rectal cancer
should preferably receive some form of neoadjuvant
treatment to downstage the tumour and enable a poten-
tially curative resection. Fluoropyrimidine-based che-
moradiation is currently a well-accepted approach in the
management of locally advanced rectal cancer with sev-
eral retrospective and prospective trials suggesting that
preoperative capecitabine is at least equivalent to infu-
sional 5-FU when combined with radiotherapy, and may
improve tumour downstaging. Since 2009, capecitabine
has been recommended by the US National Compre-
hensive Cancer Network as an acceptable alternative to
5-FU in this setting [20].
In the initial part of this study the complete pathologi-
cal response rate was 9.1%, tumour (T), lymph nodes
(N), and overall downstaging rates were 40%, 52.9%, and
49.1%, respectively, the total sphincter preservation rate
was 65.5% (36 out of 55 patients) and the rate in 27
patients with tumours located within 5 cm of the anal
opening was 37% (10 out of 27 patients) [19]. These
findings are similar to some other studies using single-
agent capecitabine, such as Dunst et al. [23] and Craven
et al [24] where the complete pathological response
rates were 7% and 9%, respectively; that said, in small
studies with oral capecitabine the complete pathological
response rate has ranged from 0 to 31% [23-39], while
in the study by Kim et al. [40], which is one of the lar-
gest studies to date, the rate was 12%. It is noteworthy
that the findings from this study are comparable to stu-
dies using single-agent 5-FU [41].
Overall, a number of phase II studies with comparable
d e s i g n st ot h a tu s e dh e r eh a v es h o w nf a v o r a b l et o x i c i t y
profiles and pathological complete response rates with
capecitabine chemoradiotherapy [25-39]. Thus, these
studies have shown comparable results suggesting that
the combination of capecitabine and pelvic radiation is
safe and effective and that capecitabine can replace con-
tinuous infusional 5-FU. The toxicity of the combination
of capecitabine chemotherapy and radiotherapy was low,
as expected, and has been reported elsewhere [22]. The
most frequent side-effect of the preoperative combined
Figure 4 Overall survival (n = 57).
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Page 6 of 8therapy was dermatitis (grade 3 in 19 patients). These
safety data compare favorably with the results of other
phase I/II studies in rectal cancers. Long-term toxicity
found the proportion of patients with severe late
(SOMA grade 3 and 4) rectal, bladder and sexual toxi-
city was 40%, 19.2% and 51.7%, respectively.
In 2008, Dunst et al. [23] was the first to report long-
term follow-up on survival and local control in patients
with locally advanced rectal cancer having undergone
neoadjuvant capecitabine-based chemoradiotherapy fol-
lowed by surgery. Here, in what we believe to be only the
second long-term follow-up, in 55 patients with locally
advanced rectal cancer who underwent surgery considered
curative the 5-year overall survival rate, recurrence-free
survival rate, and local control rate were 61.4%, 52.4%, and
87.4%, respectively. The 5-year overall survival reported
here is similar to the 65% reported by Dunst et al. [23].
However, the rate of local recurrence reported here
(12.3%) was lower than the cumulative risk of local recur-
rence after 5 years reported by Dunst et al. [21] (17%).
While many questions regarding the use of adjuvant
therapy in patients with locally advanced rectal cancer
have yet to be answered, and data regarding capecita-
bine in this setting are limited, it is clear that capecita-
bine is an effective and more convenient alternative to
5-FU when combined with radiotherapy in the preo-
perative treatment of patients with locally advanced rec-
tal cancer. A number of on-going trials are taking place
that incorporate capecitabine as an integral part of the
design with the aim to refine the management of this
patient group and, as such, is likely to assume a major
role in the treatment of rectal cancer in the future.
Conclusion
The results of this long-term study confirm data from
other non-randomised studies that capecitabine-based
preoperative chemoradiation is a feasible treatment
option for locally advanced rectal cancer, with positive
5-year overall survival, recurrence-free survival, and
local control rates. Complete pathological response
rates were similar to those reported with single-agent
5-FU.
Abbreviation
5-FU: 5-fluorouracil.
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